Kliniken Essen-Mitte

Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial (2019) Schneeweiss A, Moebus V, Tesch H, Hanusch C, Denkert C, Luebbe K, Huober J, et al. Journal article A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB) (2019) Mayer IA, Prat A, Egle D, Blau S, Alejandro Perez Fidalgo J, Gnant M, Fasching P, et al. Journal article Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial (2019) Denkert C, Budczies J, Regan MM, Loibl S, Dell’Orto P, von Minckwitz G, Mastropasqua MG, et al. Journal article Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients (2019) Nabieva N, Häberle L, Brucker SY, Janni W, Volz B, Löhberg C, Hartkopf AD, et al. Journal article Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC) (2018) Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, et al. Conference contribution Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials (2018) von Waldenfels G, Loibl S, Furlanetto J, Machleidt A, Lederer B, Denkert C, Hanusch C, et al. Journal article Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials (2018) Van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marme F, Stickeler E, et al. Journal article Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients (2018) Nabieva N, Kellner S, Fehm T, Häberle L, De Waal J, Rezai M, Baier B, et al. Journal article Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study (2018) Nabieva N, Fehm T, Häberle L, De Waal J, Rezai M, Baier B, Baake G, et al. Journal article Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study (2018) Dixon-Suen SC, Nagle CM, Thrift AP, Pharoah PDP, Ewing A, Pearce CL, Zheng W, et al. Journal article